Skip to content
Menu

Milestone Pharmaceuticals Inc. MIST

Full chart Compare
Set alert

Price alert · MIST

All alert types
0.37 USD -0.03 (-7.06%)

Regular-session close

0.38 +0.01 +1.81%

After hours · Nov 20, 4:28 PM ET

0.3705 Day range 0.40
0.362 52-week range 3.06
YTD
-81.63%
1 year
-83.94%

Fundamental scorecard

6 of 25 checks passed on MIST’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Value 1 of 5

  • Failed:P/E below its own 5-year median No profit over the last 12 months, so no P/E.
  • Failed:P/E under 20 No profit over the last 12 months, so no P/E.
  • Passed:Price to sales below its own 5-year median Price to sales 8.7 against a 5-year median of 41.5.
  • Failed:Price to book below its own 5-year median Shareholders’ equity is negative.
  • Failed:Free cash flow yield above 4% Free cash flow of -77.1M is -167.0% of the market value.

Growth 1 of 5

  • No data:Revenue grew over the last year Not enough data to decide.
  • No data:Revenue grew more than 5% a year over five years Not enough data to decide.
  • Passed:Earnings per share grew over the last year EPS -0.74 against -0.82 in the 12 months before.
  • Failed:Earnings per share grew more than 5% a year over five years EPS -1.70 in FY 2020, -0.75 in FY 2025.
  • No data:Analysts expect higher earnings per share over the next year No analyst estimate.

Profitability 1 of 5

  • Failed:Profitable over the last year Net income of -97.9M over the last 12 months.
  • Failed:Profitable in each of the last five fiscal years A profit in 0 of the last 5 fiscal years.
  • Failed:Return on equity above 15% Return on equity of -1370.6%.
  • Passed:Net margin above its 5-year average Net margin of -1844.8% against a 5-year average of -2875.2%.
  • Failed:Free cash flow is at least 80% of net income No profit over the last 12 months to compare with.

Financial health 3 of 5

  • Passed:Short-term assets cover short-term liabilities Short-term assets of 162M against short-term liabilities of 25.8M.
  • Passed:Short-term assets cover long-term liabilities Short-term assets of 162M against long-term liabilities of 143M.
  • Passed:Net debt under 40% of equity More cash than debt: 145M of cash against 144M of debt.
  • Failed:Operating cash flow covers at least 20% of debt Operating cash flow of -76.8M is -53.4% of debt.
  • Failed:Operating profit covers interest at least 3 times Operating profit is -7.1 times the interest expense.

Dividend 0 of 5

  • Failed:Pays a dividend No dividend paid.
  • Failed:Yield above 1.5% No dividend paid.
  • Failed:Pays out under 75% of profit No dividend paid.
  • Failed:Covered by free cash flow No dividend paid.
  • Failed:Not cut in the last five fiscal years No dividend paid.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Financial position

What MIST owns and owes, as of Sep 30, 2026

Short term and long term

Balance sheet · 163M of assets

Liabilities exceed assets, so there is no shareholders’ equity to show.

Debt, equity and cash by year

Now: 1.59M more cash than debt

Fiscal years, then the newest quarter. Cash includes short-term investments.

From the company’s SEC filings.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

-4.93 Distress zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

3 / 9 Weak

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

C+2 / 5 overall

  • DCF 3
  • Return on Equity 5
  • Return on Assets 1
  • Debt / Equity 1
  • P/E 1
  • P/B 1

Valuation

P/E -2.7×
P/S 110×
P/B 4.1×
P/FCF -3.4×
EV/EBITDA -2.6×
EV/Sales 100×
FCF Yield -29.1%

Profitability

Gross Margin 92.6%
Operating Margin -4041.7%
Net Margin -4078.8%
ROE -151.0%
ROIC -62.0%
ROA -55.5%

Growth (YoY)

Revenue 0.0%
Operating Income -48.4%
EPS (diluted) -11.9%
Free Cash Flow -70.8%

Financial Health

Current Ratio 8.0×
Quick Ratio 8.0×
Debt / Equity 1.4×
Net Debt / EBITDA 0.2×
Interest Coverage -16.3×

Dividends

Dividend Yield 0.0%
Payout Ratio 0.0%

Annual · latest fiscal year ends 2025-12-31